RxDoctor Payments Data

Gregory Byrd, MD

Internal Medicine · Woodstock, VANPI 1396744488

Payments from drug & device makers

$844in general payments, 2019–2025

Across 50 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$157
  • Novo Nordisk$147
  • AstraZeneca$67
  • Merck$57
  • Exact Sciences$56
  • Lilly USA, LLC$49
  • plus $311 from 12 others

What the payments were for

  • Food & beverage$844100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$844 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$10,410
Medicare patients
773
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin347$265,844
EliquisApixaban245$198,845
OzempicSemaglutide122$139,237
MounjaroTirzepatide113$116,130
Dupixent SyringeDupilumab15$56,065
JanuviaSitagliptin Phosphate45$43,482
FarxigaDapagliflozin Propanediol40$38,294
MyrbetriqMirabegron41$35,336
XareltoRivaroxaban37$35,308
EntrestoSacubitril/Valsartan31$21,690
Tresiba Flextouch U-200Insulin Degludec14$21,636
Breo ElliptaFluticasone/Vilanterol40$17,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,281
Combivent RespimatIpratropium/Albuterol Sulfate14$13,324
TrulicityDulaglutide12$11,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$42$279,168361 claims
PfizerEliquis, Premarin$157$204,703256 claims
Novo NordiskOzempic$147$139,237122 claims
Lilly USA, LLCMounjaro, Trulicity$49$127,526125 claims
AstraZenecaFarxiga, Symbicort$67$44,22156 claims
MerckJanuvia$57$43,48245 claims
Johnson & JohnsonXarelto$15$35,30837 claims
GSKBreo Ellipta, Trelegy Ellipta$35$32,47457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Woodstock

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →